4 research outputs found
Covid-19 and cancer therapy: Interrelationships and management of cancer cases in the era of Covid-19
'e COVID-19 global epidemic poses this generation’s biggest worldwide public health challenge probably since the 1918
influenza epidemic. Recent reports on two new variants have triggered a dramatic upsurge in research to understand the
pandemic, primarily focussing on the virology, triggers, clinical characteristics, and diagnostic tests including the prevention and
management of the novel coronavirus. Whilst such studies are important in managing the present medical emergency, there is a
need for further work to include interdependencies between the epidemic and other illnesses. 'is will help in developing effective
approaches to treat and manage associated diseases in both the short and the long term. In this regard, people living with cancer
are a subgroup that is highly vulnerable to respiratory infections and acute pneumonitis similar to the one caused by the COVID19 virus. 'is is because the state of their immunity is compromised due to malignancy and the adverse effects of anticancer
treatments. With annual cancer projections rising globally and an estimated 70 percent of all cancer-related deaths occurring in
low- and middle-income countries, the patient population with impaired immune systems that could be adversely impacted by
COVID-19 is only anticipated to rise. In this review, we delve into the challenges and health risks facing cancer patients and cancer
treatment in the COVID-19 context, with suggestions into viable measures which can be taken to minimize exposure to the risk of
contracting COVID-19 for this vulnerable subgroup. New mutations and the prospects offered by vaccines development and how
they relate to this class of patients are also discussed
New palladium(II) and platinum(II) complexes based on pyrrole Schiff bases: synthesis, characterization, X-ray structure, and anticancer activity
New palladium (Pd)II and platinum (Pt)II complexes (C1−C5) from the Schiff
base ligands, R-(phenyl)methanamine (L1), R-(pyridin-2-yl)methanamine (L2), and R-(furan2-yl)methanamine (L3) (R-(E)-N-((1H-pyrrol-2-yl) methylene)) are herein reported. The
complexes (C1−C5) were characterized by FTIR, 1
H and 13C NMR, UV−vis, and
microanalyses. Single-crystal X-ray crystallographic analysis was performed for the two ligands
(L1−L2) and a Pt complex. Both L1 and L2 belong to P21/n monoclinic and P-1 triclinic space
systems, respectively. The complex C5 belongs to the P21/c monoclinic space group. The
investigated molar conductivity of the complexes in DMSO gave the range 4.0−8.8 μS/cm,
suggesting neutrality, with log P values ≥ 1.2692 ± 0.004, suggesting lipophilicity. The
anticancer activity and mechanism of the complexes were investigated against various human
cancerous (Caco-2, HeLa, HepG2, MCF-7, and PC-3) and noncancerous (MCF-12A) cell lines
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Apopercentage
assays, respectively. C5 demonstrated strong DNA-binding affinity for calf thymus DNA (CTDNA) with a binding constant of 8.049 × 104 M−1
. C3 reduced cell viability of all the six cell
lines, which included five cancerous cell lines, by more than 80%. The C5 complex also demonstrated remarkably high selectivity
with no cytotoxic activity toward the noncancerous breast cell line but reduced the viability of the five cancerous cell lines, which
included one breast cancer cell line, by more than 60%. Further studies are required to evaluate the selective toxicity of these two
complexes and to fully understand their mechanism of actio